[ Business | US Market | Industry | IPO | S&P | International | PRNews | BizWire | Finance Home ]
ST. PAUL, Minn., Jan. 15 /PRNewswire/ -- Diametrics Medical, Inc. (Nasdaq-NNM: DMED - news) today announced that it has received FDA clearance to market its Neotrend(TM) product, the first and only multiparameter system for direct continuous monitoring of blood gases (oxygen, carbon dioxide and acidity) and temperature in critically ill premature babies.
The innovative Neotrend System uses a tiny fiber optic sensor (.5mm in diameter) and a monitor to continuously measure blood gases and temperature. The sensor is inserted through an Umbilical Artery Catheter into the infant's descending Aorta, so it is unaffected by changes in peripheral circulation which impact existing monitoring technology. The system also includes a detachable Patient Data Module for storing patient data if the patient requires moving to an alternative treatment site.
``Blood gas and temperature monitoring is critical in stabilizing these newborns,'' said Roy Johnson, Executive Vice President of Diametrics and President of Diametrics Medical, Ltd. which developed and manufactures the system. ``In ventilation therapy, if infants receive improper levels of oxygen or their carbon dioxide levels change too rapidly, complications may occur, such as permanently impaired vision, brain damage or cerebral hemorrhage. Neotrend is the first and only product to provide direct continuous monitoring of these blood gases, while minimizing the need to withdraw blood. This is essential given the small blood volume of premature infants,'' he added.
Dr. Tony Ducker, a Consultant Neonatalogist who has been using Neotrend at All Saints Hospital in Chatham, England, stated, ``It's working well and is of enormous benefit, because we can respond quickly to changes. We don't have to touch the baby as frequently, so these delicate infants are disturbed less often. More importantly, we don't have to take blood, which means we don't have to replace it through blood transfusions.'' Dr. Ducker concluded, ``These babies are very much at risk, so knowing exactly what is happening with their blood gas levels at any one moment, and being able to change things before they get out of hand, is a big step in improving their care.''
Diametrics Medical, Inc. is a leader in critical care technology. The company is dedicated to creating solutions that improve the quality of health care delivery through products and services that provide immediate, accurate and cost-effective time-critical blood analysis. Additional information is available at the Company's Web site, http://www.diametrics.com
Statements regarding the company's expectations about new and existing products, future financial performance and other forward looking statements are subject to various risks and uncertainties, including, without limitation, demand and acceptance of new and existing products, technological advances and product obsolescence, competitive factors and the availability of capital to finance growth. These and other risks are discussed in greater detail in the company's filings with the Securities and Exchange Commission.
SOURCE: Diametrics Medical, Inc.
|More Quotes and News:||Diametrics Medical Inc (Nasdaq:DMED - news)|
|Related News Categories: medical/pharmaceutical|